Global healthcare investment firm OrbiMed has secured $4.3 billion in commitments across its four investment funds: OrbiMed Private Investments IX, OrbiMed Asia Partners V, and OrbiMed Royalty & Credit Opportunities IV. These funds will fuel global investments, spanning from early-stage startups nurtured by OrbiMed to growth capital opportunities. A diverse array of investors, including medical institutions, endowments, foundations, pension funds, sovereign wealth funds, and family offices, have participated. OrbiMed specializes in custom financing solutions encompassing equity, credit, and royalty-based options for innovative ventures in healthcare sub-sectors such as biopharmaceuticals, medical devices, diagnostics, and technology-driven healthcare services. Managing Partner Carter Neild expressed gratitude for their long-standing partners’ support and vowed to meet their high expectations in the future.
OrbiMed, a global healthcare investment firm raises $4.3B in commitments across its four investment funds: OrbiMed Private Investments IX, OrbiMed Asia Partners V and OrbiMed Royalty & Credit Opportunities IV.
The $4.3B will be used to invest globally, from the seed stage for start-ups incubated by OrbiMed through growth capital opportunities. Investors in these new funds include a broad range of medical institutions, university endowments, foundations, pension funds, sovereign wealth funds and family offices.
Investment Thesis
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
OrbiMed works closely with its portfolio companies to provide tailored financing solutions, which can include equity, credit and royalty-based financing. OrbiMed focuses on innovative and growth-oriented opportunities across healthcare sub-sectors, including biopharmaceuticals, medical devices, diagnostics and technology-enabled healthcare services.
“OrbiMed is deeply appreciative of the continued support we’ve received from many long-standing partners who’ve invested in these funds,” said Carter Neild, a Managing Partner of OrbiMed. “We will endeavor to meet our partners’ high expectations in the coming years.”
Source: Hitconsultant
